Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Transcriptome analysis of human monocytic cells infected with Burkholderia species and exploration of pentraxin-3 as part of the innate immune response against the organisms.

Aschenbroich SA, Lafontaine ER, Lopez MC, Baker HV, Hogan RJ.

BMC Med Genomics. 2019 Sep 6;12(1):127. doi: 10.1186/s12920-019-0575-7.

2.

Antibodies Are Major Drivers of Protection against Lethal Aerosol Infection with Highly Pathogenic Burkholderia spp.

Hogan RJ, Lafontaine ER.

mSphere. 2019 Jan 2;4(1). pii: e00674-18. doi: 10.1128/mSphere.00674-18.

3.

Persistence of Moraxella catarrhalis in Chronic Obstructive Pulmonary Disease and Regulation of the Hag/MID Adhesin.

Murphy TF, Brauer AL, Pettigrew MM, LaFontaine ER, Tettelin H.

J Infect Dis. 2019 Apr 16;219(9):1448-1455. doi: 10.1093/infdis/jiy680.

PMID:
30496439
4.

Use of Immunohistochemistry to Demonstrate In Vivo Expression of the Burkholderia mallei Virulence Factor BpaB During Experimental Glanders.

Zimmerman SM, Long ME, Dyke JS, Jelesijevic TP, Michel F, Lafontaine ER, Hogan RJ.

Vet Pathol. 2018 Mar;55(2):258-267. doi: 10.1177/0300985817736113. Epub 2017 Nov 16.

PMID:
29145795
5.

Stringently Defined Otitis Prone Children Demonstrate Deficient Naturally Induced Mucosal Antibody Response to Moraxella catarrhalis Proteins.

Ren D, Murphy TF, Lafontaine ER, Pichichero ME.

Front Immunol. 2017 Aug 11;8:953. doi: 10.3389/fimmu.2017.00953. eCollection 2017.

6.

Serum antibody response to Moraxella catarrhalis proteins in stringently defined otitis prone children.

Ren D, Almudevar AL, Murphy TF, Lafontaine ER, Campagnari AA, Luke-Marshall N, Pichichero ME.

Vaccine. 2019 Jul 26;37(32):4637-4645. doi: 10.1016/j.vaccine.2017.07.027. Epub 2017 Jul 26.

PMID:
28755833
7.

Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.

Zimmerman SM, Dyke JS, Jelesijevic TP, Michel F, Lafontaine ER, Hogan RJ.

Infect Immun. 2017 Jul 19;85(8). pii: e00102-17. doi: 10.1128/IAI.00102-17. Print 2017 Aug.

8.

Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches.

Aschenbroich SA, Lafontaine ER, Hogan RJ.

Expert Rev Vaccines. 2016 Sep;15(9):1163-81. doi: 10.1586/14760584.2016.1170598. Epub 2016 Apr 20. Review.

PMID:
27010618
9.

Hypothiocyanite produced by human and rat respiratory epithelial cells inactivates extracellular H1N2 influenza A virus.

Gingerich A, Pang L, Hanson J, Dlugolenski D, Streich R, Lafontaine ER, Nagy T, Tripp RA, Rada B.

Inflamm Res. 2016 Jan;65(1):71-80. doi: 10.1007/s00011-015-0892-z. Epub 2015 Nov 25.

PMID:
26608498
10.

Serum antibody response to Moraxella catarrhalis proteins OMP CD, OppA, Msp22, Hag, and PilA2 after nasopharyngeal colonization and acute otitis media in children.

Ren D, Almudevar AL, Murphy TF, Lafontaine ER, Campagnari AA, Luke-Marshall N, Casey JR, Pichichero ME.

Vaccine. 2015 Oct 26;33(43):5809-5814. doi: 10.1016/j.vaccine.2015.09.023. Epub 2015 Sep 21.

11.

The Autotransporter BpaB Contributes to the Virulence of Burkholderia mallei in an Aerosol Model of Infection.

Zimmerman SM, Michel F, Hogan RJ, Lafontaine ER.

PLoS One. 2015 May 20;10(5):e0126437. doi: 10.1371/journal.pone.0126437. eCollection 2015.

12.

Use of the common marmoset to study Burkholderia mallei infection.

Jelesijevic T, Zimmerman SM, Harvey SB, Mead DG, Shaffer TL, Estes DM, Michel F, Quinn FD, Hogan RJ, Lafontaine ER.

PLoS One. 2015 Apr 10;10(4):e0124181. doi: 10.1371/journal.pone.0124181. eCollection 2015.

13.

Delineating the importance of serum opsonins and the bacterial capsule in affecting the uptake and killing of Burkholderia pseudomallei by murine neutrophils and macrophages.

Mulye M, Bechill MP, Grose W, Ferreira VP, Lafontaine ER, Wooten RM.

PLoS Negl Trop Dis. 2014 Aug 21;8(8):e2988. doi: 10.1371/journal.pntd.0002988. eCollection 2014 Aug.

14.

Characterization of an autotransporter adhesin protein shared by Burkholderia mallei and Burkholderia pseudomallei.

Lafontaine ER, Balder R, Michel F, Hogan RJ.

BMC Microbiol. 2014 Apr 14;14:92. doi: 10.1186/1471-2180-14-92.

15.

Moraxella catarrhalis expresses a cardiolipin synthase that impacts adherence to human epithelial cells.

Buskirk SW, Lafontaine ER.

J Bacteriol. 2014 Jan;196(1):107-20. doi: 10.1128/JB.00298-13. Epub 2013 Oct 18.

16.

Use of a safe, reproducible, and rapid aerosol delivery method to study infection by Burkholderia pseudomallei and Burkholderia mallei in mice.

Lafontaine ER, Zimmerman SM, Shaffer TL, Michel F, Gao X, Hogan RJ.

PLoS One. 2013 Oct 2;8(10):e76804. doi: 10.1371/journal.pone.0076804. eCollection 2013.

17.

Use of the Chinchilla model to evaluate the vaccinogenic potential of the Moraxella catarrhalis filamentous hemagglutinin-like proteins MhaB1 and MhaB2.

Shaffer TL, Balder R, Buskirk SW, Hogan RJ, Lafontaine ER.

PLoS One. 2013 Jul 2;8(7):e67881. doi: 10.1371/journal.pone.0067881. Print 2013.

18.

Moraxella catarrhalis uses a twin-arginine translocation system to secrete the β-lactamase BRO-2.

Balder R, Shaffer TL, Lafontaine ER.

BMC Microbiol. 2013 Jun 19;13:140. doi: 10.1186/1471-2180-13-140.

19.

Comparative analysis of the humoral immune response to Moraxella catarrhalis and Streptococcus pneumoniae surface antigens in children suffering from recurrent acute otitis media and chronic otitis media with effusion.

Verhaegh SJ, Stol K, de Vogel CP, Riesbeck K, Lafontaine ER, Murphy TF, van Belkum A, Hermans PW, Hays JP.

Clin Vaccine Immunol. 2012 Jun;19(6):914-8. doi: 10.1128/CVI.05630-11. Epub 2012 Apr 25.

20.

Temporal development of the humoral immune response to surface antigens of Moraxella catarrhalis in young infants.

Verhaegh SJ, de Vogel CP, Riesbeck K, Lafontaine ER, Murphy TF, Verbrugh HA, Jaddoe VW, Hofman A, Moll HA, van Belkum A, Hays JP.

Vaccine. 2011 Aug 5;29(34):5603-10. doi: 10.1016/j.vaccine.2011.06.019. Epub 2011 Jun 23.

PMID:
21704103
21.

Identification of Burkholderia mallei and Burkholderia pseudomallei adhesins for human respiratory epithelial cells.

Balder R, Lipski S, Lazarus JJ, Grose W, Wooten RM, Hogan RJ, Woods DE, Lafontaine ER.

BMC Microbiol. 2010 Sep 28;10:250. doi: 10.1186/1471-2180-10-250.

22.

Hag mediates adherence of Moraxella catarrhalis to ciliated human airway cells.

Balder R, Krunkosky TM, Nguyen CQ, Feezel L, Lafontaine ER.

Infect Immun. 2009 Oct;77(10):4597-608. doi: 10.1128/IAI.00212-09. Epub 2009 Aug 10.

23.

Identification of domains of the Hag/MID surface protein recognized by systemic and mucosal antibodies in adults with chronic obstructive pulmonary disease following clearance of Moraxella catarrhalis.

LaFontaine ER, Snipes LE, Bullard B, Brauer AL, Sethi S, Murphy TF.

Clin Vaccine Immunol. 2009 May;16(5):653-9. doi: 10.1128/CVI.00460-08. Epub 2009 Mar 25.

24.

Laboratory Maintenance of Moraxella catarrhalis.

Balder R, Lafontaine ER.

Curr Protoc Microbiol. 2008 Nov;Chapter 6:Unit 6B.1. doi: 10.1002/9780471729259.mc06b01s11.

PMID:
19016443
25.

Gabapentin does not reduce post-thoracotomy shoulder pain: a randomized, double-blind placebo-controlled study.

Huot MP, Chouinard P, Girard F, Ruel M, Lafontaine ER, Ferraro P.

Can J Anaesth. 2008 Jun;55(6):337-43. doi: 10.1007/BF03021488.

PMID:
18566196
26.

Regions important for the adhesin activity of Moraxella catarrhalis Hag.

Bullard B, Lipski S, Lafontaine ER.

BMC Microbiol. 2007 Jul 3;7:65.

27.

The Moraxella catarrhalis outer membrane protein CD contains two distinct domains specifying adherence to human lung cells.

Akimana C, Lafontaine ER.

FEMS Microbiol Lett. 2007 Jun;271(1):12-9. Epub 2007 Mar 28.

28.

Moraxella catarrhalis strain O35E expresses two filamentous hemagglutinin-like proteins that mediate adherence to human epithelial cells.

Balder R, Hassel J, Lipski S, Lafontaine ER.

Infect Immun. 2007 Jun;75(6):2765-75. Epub 2007 Mar 19.

29.

Identification of a Moraxella catarrhalis gene that confers adherence to various human epithelial cell lines in vitro.

Lipski SL, Holm MM, Lafontaine ER.

FEMS Microbiol Lett. 2007 Feb;267(2):207-13. Epub 2006 Dec 8.

30.
31.

Identification of a Francisella tularensis LVS outer membrane protein that confers adherence to A549 human lung cells.

Melillo A, Sledjeski DD, Lipski S, Wooten RM, Basrur V, Lafontaine ER.

FEMS Microbiol Lett. 2006 Oct;263(1):102-8.

32.

Acetaminophen decreases early post-thoracotomy ipsilateral shoulder pain in patients with thoracic epidural analgesia: a double-blind placebo-controlled study.

Mac TB, Girard F, Chouinard P, Boudreault D, Lafontaine ER, Ruel M, Ferraro P.

J Cardiothorac Vasc Anesth. 2005 Aug;19(4):475-8.

PMID:
16085252
33.

Hag directly mediates the adherence of Moraxella catarrhalis to human middle ear cells.

Bullard B, Lipski SL, Lafontaine ER.

Infect Immun. 2005 Aug;73(8):5127-36.

34.

The UspA2 protein of Moraxella catarrhalis is directly involved in the expression of serum resistance.

Attia AS, Lafontaine ER, Latimer JL, Aebi C, Syrogiannopoulos GA, Hansen EJ.

Infect Immun. 2005 Apr;73(4):2400-10.

35.

Moraxella catarrhalis coaggregates with Streptococcus pyogenes and modulates interactions of S. pyogenes with human epithelial cells.

Lafontaine ER, Wall D, Vanlerberg SL, Donabedian H, Sledjeski DD.

Infect Immun. 2004 Nov;72(11):6689-93.

36.

The Moraxella catarrhalis porin-like outer membrane protein CD is an adhesin for human lung cells.

Holm MM, Vanlerberg SL, Foley IM, Sledjeski DD, Lafontaine ER.

Infect Immun. 2004 Apr;72(4):1906-13.

37.

The Hag protein of Moraxella catarrhalis strain O35E is associated with adherence to human lung and middle ear cells.

Holm MM, Vanlerberg SL, Sledjeski DD, Lafontaine ER.

Infect Immun. 2003 Sep;71(9):4977-84.

38.

Identification of a Moraxella catarrhalis outer membrane protein exhibiting both adhesin and lipolytic activities.

Timpe JM, Holm MM, Vanlerberg SL, Basrur V, Lafontaine ER.

Infect Immun. 2003 Aug;71(8):4341-50.

39.

A hag mutant of Moraxella catarrhalis strain O35E is deficient in hemagglutination, autoagglutination, and immunoglobulin D-binding activities.

Pearson MM, Lafontaine ER, Wagner NJ, St Geme JW 3rd, Hansen EJ.

Infect Immun. 2002 Aug;70(8):4523-33.

40.
41.

RegA, iron, and growth phase regulate expression of the Pseudomonas aeruginosa tol-oprL gene cluster.

Duan K, Lafontaine ER, Majumdar S, Sokol PA.

J Bacteriol. 2000 Apr;182(8):2077-87.

42.

The UspA1 protein and a second type of UspA2 protein mediate adherence of Moraxella catarrhalis to human epithelial cells in vitro.

Lafontaine ER, Cope LD, Aebi C, Latimer JL, McCracken GH Jr, Hansen EJ.

J Bacteriol. 2000 Mar;182(5):1364-73.

43.

Characterization of the Moraxella catarrhalis uspA1 and uspA2 genes and their encoded products.

Cope LD, Lafontaine ER, Slaughter CA, Hasemann CA Jr, Aebi C, Henderson FW, McCracken GH Jr, Hansen EJ.

J Bacteriol. 1999 Jul;181(13):4026-34.

44.

Phenotypic effect of isogenic uspA1 and uspA2 mutations on Moraxella catarrhalis 035E.

Aebi C, Lafontaine ER, Cope LD, Latimer JL, Lumbley SL, McCracken GH Jr, Hansen EJ.

Infect Immun. 1998 Jul;66(7):3113-9.

46.

Identification and characterization of the tolQRA genes of Pseudomonas aeruginosa.

Dennis JJ, Lafontaine ER, Sokol PA.

J Bacteriol. 1996 Dec;178(24):7059-68.

47.
48.

Oropharyngeal dysphagia and operations on the upper esophageal sphincter.

Duranceau A, Lafontaine ER, Taillefer R, Jamieson GG.

Surg Annu. 1987;19:317-62. Review. No abstract available.

PMID:
3547715
49.

Effects of total fundoplication on function of the esophagus after myotomy for achalasia.

Duranceau A, LaFontaine ER, Vallieres B.

Am J Surg. 1982 Jan;143(1):22-8.

PMID:
7053651

Supplemental Content

Loading ...
Support Center